Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.
Overall analgesic effect as measured by total pain relief over 12 hours.
Post-op dental pain over 6 hours as measured by pain intensity/relief scores, patient global assessment, and time to perceptible/meaningful pain relief.
Frequently asked questions about MK0966, rofecoxib
What is MK0966 (rofecoxib) used for?
MK0966, also known as rofecoxib, is an investigational small molecule being studied for the treatment of osteoarthritis, postoperative pain, and pain following arthroscopic surgery. It is in Phase 3 clinical development for these musculoskeletal and pain-related conditions.
Who makes MK0966 (rofecoxib)?
MK0966 (rofecoxib) is being developed by Merck & Company, Inc., a pharmaceutical company listed on the stock exchange under the ticker symbol MRK. Merck is conducting clinical trials to evaluate the drug's safety and efficacy in patients with osteoarthritis and various pain conditions.
What phase is MK0966 (rofecoxib) in?
MK0966 (rofecoxib) is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in completed Phase 3 trials for osteoarthritis, postoperative pain, and pain following arthroscopic surgery.
What clinical trials has MK0966 (rofecoxib) been in?
MK0966 (rofecoxib) has been studied in five completed Phase 3 clinical trials. These include NCT00092313 for postoperative dental pain, NCT00092352 and NCT00092365 for osteoarthritis, and NCT00390260 for pain following arthroscopic surgery. The trials enrolled a total of 1,366 participants.
Is MK0966 the same as rofecoxib?
Yes, MK0966 is the same as rofecoxib. The drug is referred to by both names in clinical research. Rofecoxib is the generic name, while MK0966 is the investigational code name used by the developer, Merck & Company, Inc.
What is the therapeutic area of MK0966 (rofecoxib)?
MK0966 (rofecoxib) falls under the musculoskeletal therapeutic area. It is being developed as a small molecule treatment for conditions such as osteoarthritis and various types of pain, including postoperative pain and pain following arthroscopic surgery.